CROs dMed and Clinipace Merge to Accelerate Customer Success

(VCBeat) Apr. 28, 2021 -- dMed, a clinical contract research organization (CRO) headquartered in Shanghai, China, and Clinipace, a CRO headquartered in North Carolina, USA, today announced the completion of the merger of the two companies. This combination will meet the rapidly growing needs of those two biotech, pharmaceutical and medical device companies and accelerate the development of innovative solutions to patients worldwide.

The new company will be a global CRO in midsize with more than 1,600 employees in 22 countries. It has a dominant position in terms of geographic reach, service types and therapeutic technology, rivaling leading counterparts. The new company's service capabilities in North America, Asia Pacific, Europe and Latin America will compete for head-on with the world-class services offered by leading CRO.

Dr. Tan Lingshi, currently Chairman and Chief Executive Officer of dMed, will serve as Chairman and Global CEO of the new company. Jason Monteleone, currently Chief Executive Officer of Clinipace, will serve as Chief Business and Strategy Officer of the new company.

Founded in 2016 by Dr. Tan Lingshi, former Vice President of Pfizer Global Clinical Operations and the first General Manager of Pfizer China R&D Center, dMed is a full-service CRO operated by a world-class team providing clinical development and registration services. Since its establishment, dMed has achieved rapid development in the tide of rapid internationalization of clinical trials. dMed took its first step toward globalization with the acquisition of US-based Target Health in 2019. Target Health is a comprehensive technology-driven CRO with particular expertise in digital capabilities and registration matters.

Clinipace has nearly 25 years of experience in extensive clinical trial services and registration, as well as expertise in core therapeutic areas such as oncology, nephrology, rare diseases, gastroenterology and women's health. The company has a worldwide reputation and has successfully established a wide range of strategic partnerships with many clients.